Articles > Lymphoma

  1. When Sleep Is Elusive

    By Abby Henry, Oncology Content Manager, PearlPoint Cancer Support | June 2016 A lot of cancer patients and people in general have trouble getting a good night’s sleep. However, sleep is very important, especially during cancer treatment to promote healing. If you are having trouble sleeping, the first thing to do is figure out what is at the root of your difficulty sleeping—stress and anxiety, side effects, lack of peaceful sleeping environment? Once you know what is making sleep e...

    Read More
  2. We All Scream for Ice Cream

    By Margaret Martin, RD, MS, LDN | July 2016 What is America's favorite dessert? Ice cream is definitely in the running! Did you know that ice cream can be beneficial for cancer survivors? Ice cream can help you manage side effects from cancer and cancer treatment such as weight loss, sore mouth, sore throat, and change in taste and smell. During cancer treatment, sometimes it is difficult to find a food, texture, or flavor that's appealing. The possible flavors and textures of ice cream...

    Read More
  3. Cancer Wasn’t Going to Stop Me

    When I entered Rutgers University, I thought, “This is the beginning of the rest of my life.” Little did I know that virtually my entire college career I would be battling cancer. I was sick and had mono symptoms at least twice a month my entire freshman year, developed a lump on my neck the fall semester of my sophomore year, and after a surgery to remove the lump, was diagnosed with Hodgkin lymphoma. I just turned 20 and I had cancer. I thought my life was over. I kept thinking, “...

    Read More
  4. A Vaccine to Treat Mantle Cell Lymphoma?

    Ronald Levy, professor of medicine and former chief of the Division of Oncology at Stanford University School of Medicine, helped develop and test the first US Food and Drug Administration (FDA)-approved monoclonal antibody against cancer for the treatment of B-cell lymphoma. Rituximab is now a standard of treatment alone and also in combination with chemotherapy regimens. Levy is receiving LLS funding through the Translational Research Program for research into an immunotransplant...

    Read More
  5. VP Biden Addresses Researchers @ ASCO16

    Speaking from the heart, Vice President Joseph Biden addressed thousands of cancer researchers today in a packed hall at the American Society of Clinical Oncology (#ASCO16) annual meeting in Chicago, to tout his Cancer Moonshot initiative. The theme of this year’s #ASCO16 meeting, “Collective Wisdom – The Future of Patient-Centered Care and Research,” is perfectly aligned with the goals of the Moonshot, Biden told the rapt audience.

    Read More
  6. Precision Medicine and Immunotherapy @ ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting featured several significant oral scientific presentations on the blood cancers over the weekend here in Chicago. CPX-351: A session on hematological malignancies Saturday afternoon included a discussion of final data from the Phase 3 clinical trial of Celator’s drug CPX-351 (Vyxeos ®). LLS invested substantially in this study through our Therapy Acceleration Program (TAP). The study was in a small subset of elderly pati...

    Read More
  7. Putting Patients at the Center of Care at #ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting kicked off today as more than 30,000 researchers from around the world converged in Chicago to share their latest clinical findings on treatments and diagnostics for all cancers, and to exchange ideas about how to improve outcomes for cancer patients. Putting patients at the center of cancer care and research is this year’s theme at ASCO, something we at The Leukemia & Lymphoma Society (LLS) try to do every day. Sprin...

    Read More
  8. Finding New Approaches to Immunotherapy

    Helen Heslop, M.D., leads a team of scientists being funded through LLS’s Specialized Center of Research Program (SCOR). The project brings together researchers from different institutions to test a half dozen novel approaches to cancer immunotherapy – all of which harness the patient's own immune system to fight the cancer. Heslop, a professor in the Department of Medicine and Pediatrics at Baylor College of Medicine and the director of the Center for Cell and Gene Therapy, pioneered...

    Read More
  9. Significant Advance for Hodgkin Lymphoma Patients

    The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival. FDA’s approval of nivolumab (Opdivo®)...

    Read More
  10. #ASH15 Day 4: Breakthrough Therapy Designation for Novel Immunotherapy

    Yesterday we learned the exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy LLS is supporting through our Therapy Acceleration Program (TAP). The therapy, KTE-C19, being developed by Kite Pharma, is another example of a chimeric antigen receptor (CAR), an approach that genetically engineers patients’ immune T cells and reintroduces them into the body to kill cancer cells. KTE-C19 is crafted by removing patients' T cells and geneti...

    Read More